Iron Chelators Predicated on Desferrithiocin
Iron Chelators Predicated on Desferrithiocin
批准号:
8675223
负责人:
Raymond Joseph Bergeron
金额:
$61.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-02-01 至 2016-05-31
关键词:
AbbreviationsAcidsAdverse effectsAffectAlkylationAminesAnimal ModelBiologicalBiological FactorsCanis familiarisCapuchin MonkeyCell modelCellsChelating ActivityChelating AgentsChemistryClinicalClinical TrialsCooley&aposs anemiaDevelopmentEukaryotaEvaluationExcretory functionFamilyFloridaHeartHereditary hemochromatosisHumanIn VitroInjuryIronIron Chelating AgentsIron OverloadKidneyLeadLicensingLiverLongevityMammalian CellMediatingMethodsModelingMolecular WeightOrganPancreasParentsPatientsPhasePhysiciansPolyaminesPreparationPrimatesProkaryotic CellsResearchResearch Project GrantsRiskRodentSickle Cell AnemiaSiderophoresSpermidineStreptomyces antibioticusStructureSystemTestingTimeToxic effectUnited StatesUniversitiesVariantVertebral columnanalogbasedesferrithiocindesignexperienceimprovedin vivolipophilicitymetal chelatornorspermidinenovelpharmacophorepreclinical evaluationprogramstargeted deliveryuptakevector
中文摘要
描述(由申请人提供):拟议的研究项目将侧重于设计、合成、评估和开发靶向去铁硫辛酸类似物,用于治疗铁超载。医生迫切需要新的、更有效的铁螯合剂,以选择性地去除肝脏、心脏和胰腺中的铁,这些器官在地中海贫血、镰状细胞病、遗传性血色素沉着症和其他形式的铁超载患者中具有最大的铁诱导损伤风险。去铁硫肽(DFT)是一种从链霉菌中分离出来的天然铁螯合剂(铁载体),是目前发现的最有效的口服铁螯合剂之一,但其肾毒性阻碍了其临床应用。我们系统的结构-活性研究允许设计和合成类似物和衍生物,这些类似物和衍生物保留了DFT的特殊铁螯合活性,而不会对肾脏或其他器官产生不良影响。我们的先导化合物是口服活性DFT类似物(S)-2-(2,4-二羟基苯基)-4,5-二氢-4-甲基-4-噻唑羧酸[(S)-4'-(HO)- dadft(28)],其在无毛猿猴灵长类动物模型中的有效性几乎是sc DFO的三倍,已被授权给一家商业赞助商,目前正在进行I/II期临床试验。我们现在假设DFT平台可以在结构上进行编程,以靶向铁诱导损伤风险最大的器官,并进一步增强铁清除。为了验证这些假设,我们的研究计划有三个具体目标:
英文摘要
DESCRIPTION (provided by applicant): The proposed research project will focus on the design, synthesis, evaluation, and development of targeted desferrithiocin analogues for the treatment of iron overload. Physicians have a pressing clinical need for new, more effective iron-chelating agents which selectively remove iron from the liver, heart, and pancreas, the organs at greatest risk of iron-induced injury in patients with thalassemia major, sickle cell disease, hereditary hemochromatosis and other forms of iron overload. Desferrithiocin (DFT), a natural product iron chelator (siderophore) isolated from Streptomyces antibioticus, is one of the most orally effective iron chelating agents yet identified but renal toxicity precludes its clinical use. Our systematic structure-activity studies have allowed the design and synthesis of analogues and derivatives, which retain the exceptional iron-chelating activity of DFT without adverse effects on the kidneys or other organs. Our lead compound, the orally active DFT analogue (S)-2-(2,4-dihydroxyphenyl)-4,5-dihydro-4-methyl-4-thiazolecarboxylic acid [(S)-4'-(HO)-DADFT (28)], which is nearly three times as effective as sc DFO in the C. apella primate model, has been licensed to a commercial sponsor and currently is in Phase I/II clinical trials. We now hypothesize that the DFT platform can be structurally programmed to target delivery to organs at greatest risk of iron induced injury and to further enhance iron clearance. To test these hypotheses, our research plan has three specific aims:
Aim 1: to design and synthesize partition-variant desferrithiocin analogues with enhanced access to organs vulnerable to iron-induced injury (eg, liver, heart, pancreas) and/or increased iron clearing efficiency;
Aim 2: to design and synthesize polyamine-vectored desferrithiocin analogues that use the polyamine transport apparatus to gain entry into cells; and
Aim 3: to assess these new desferrithiocin analogues in physiochemical, cellular and animal models to identify safe and effective compounds for GLP preclinical evaluation in preparation for human studies.
The development of safe, effective, and well-tolerated iron-chelating agents based on DFT would be a major advance in the treatment of iron overload that would greatly enhance both the quality and length of life of affected patients in the United States and worldwide.
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Design, Synthesis, and Testing of Polyamine Vectored Iron Chelators.
多胺矢量铁螯合剂的设计、合成和测试。
DOI:
10.1055/s-0030-1258245
发表时间:
2010
期刊:
Synthesis
影响因子:
--
作者:
[Bergeron,RaymondJ, Singh,Shailendra, Bharti,Neelam, Jiang,Yi]
通讯作者:
Jiang,Yi
DOI:
10.1016/j.bmc.2015.06.059
发表时间:
2015-09-01
期刊:
Bioorganic & medicinal chemistry
影响因子:
3.5
作者:
[Bergeron RJ, Bharti N, McManis JS, Wiegand J]
通讯作者:
Wiegand J
DOI:
10.1021/jm500828f
发表时间:
2014-11-26
期刊:
Journal of medicinal chemistry
影响因子:
7.3
作者:
[Bergeron RJ, Wiegand J, McManis JS, Bharti N]
通讯作者:
Bharti N
DOI:
10.1007/s10534-010-9389-y
发表时间:
2011-04
期刊:
BIOMETALS
影响因子:
3.5
作者:
[Bergeron, Raymond J., Wiegand, Jan, Bharti, Neelam, McManis, James S., Singh, Shailendra]
通讯作者:
Singh, Shailendra
DOI:
10.1021/jm300509y
发表时间:
2012-08-23
期刊:
JOURNAL OF MEDICINAL CHEMISTRY
影响因子:
7.3
作者:
[Bergeron, Raymond J., Wiegand, Jan, Bharti, Neelam, McManis, James S.]
通讯作者:
McManis, James S.
Desferrithiocin Analogue Actinide Decorporation Agents
-
批准号:7586364
-
项目类别:
-
资助金额:$67.77万
-
财政年份:2006
-
负责人:Raymond Joseph Bergeron
-
依托单位:
Desferrithiocin Analogue Actinide Decorporation Agents
-
批准号:7267878
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2006
-
负责人:Raymond Joseph Bergeron
-
依托单位:
Iron Chelators Predicated on Desferrithiocin
-
批准号:7034671
-
项目类别:
-
资助金额:$57.92万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
Iron Chelators Predicated on Desferrithiocin
-
批准号:8081769
-
项目类别:
-
资助金额:$62.46万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
Iron Chelators Predicated on Desferrithiocin
-
批准号:7340196
-
项目类别:
-
资助金额:$56.23万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
Iron Chelators Predicated on Desferrithiocin
-
批准号:7923459
-
项目类别:
-
资助金额:$64.73万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
-
批准号:6380945
-
项目类别:
-
资助金额:$65.88万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
Iron Chelators Predicated on Desferrithiocin
-
批准号:7174871
-
项目类别:
-
资助金额:$57.02万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
ORAL IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
-
批准号:2654532
-
项目类别:
-
资助金额:$57.59万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
ORAL IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
-
批准号:2149704
-
项目类别:
-
资助金额:$51.51万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
ORAL IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
-
批准号:2331462
-
项目类别:
-
资助金额:$56.8万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
-
批准号:6517345
-
项目类别:
-
资助金额:$66.35万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
Iron Chelators Predicated on Desferrithiocin
-
批准号:6866931
-
项目类别:
-
资助金额:$59.12万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
-
批准号:6718935
-
项目类别:
-
资助金额:$52.99万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
ORAL IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
-
批准号:2872219
-
项目类别:
-
资助金额:$58.08万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
ORAL IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
-
批准号:2149705
-
项目类别:
-
资助金额:$55.46万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
-
批准号:6127919
-
项目类别:
-
资助金额:$69.64万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
Iron Chelators Predicated on Desferrithiocin
-
批准号:8291416
-
项目类别:
-
资助金额:$62.59万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
-
批准号:6635036
-
项目类别:
-
资助金额:$64.79万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
Iron Chelators Predicated on Desferrithiocin
-
批准号:8470620
-
项目类别:
-
资助金额:$59.96万
-
财政年份:1995
-
负责人:Raymond Joseph Bergeron
-
依托单位:
国内基金
海外基金
登录
查看更多内容
抗禾谷镰刀菌3-Decalinoyltetramic Acids类天然产物的挖掘及基于“靶标垂钓”策略的作用机制研究
-
批准号:32470420
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2024
-
负责人:赵栋霖
-
依托单位:
真菌中同一PKS-NRPS基因簇合成两种不同骨架tetramic acids机制研究
-
批准号:32470051
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2024
-
负责人:张伟
-
依托单位:
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
-
批准号:22007039
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:王黎明
-
依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:朱义广
-
依托单位:
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
-
批准号:21372217
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:袁伟成
-
依托单位:
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
-
批准号:21172061
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2011
-
负责人:许新华
-
依托单位:
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
-
批准号:21176225
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:童少平
-
依托单位:
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
-
批准号:81072511
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:严江伟
-
依托单位:
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
-
批准号:30660215
-
项目类别:地区科学基金项目
-
资助金额:21.0万元
-
批准年份:2006
-
负责人:王世范
-
依托单位: